Analyst Price Target is $6.67
▲ +51.86% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Bioventus in the last 3 months. The average price target is $6.67, with a high forecast of $7.00 and a low forecast of $6.00. The average price target represents a 51.86% upside from the last price of $4.39.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Bioventus. This Buy consensus rating has held steady for over two years.
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.